Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Drug Synergism. Found 11 abstracts

Nieborowska-Skorska M, Maifrede S, Dasgupta Y, Sullivan K, Flis S, Le BV, Solecka M, Belyaeva EA, Kubovcakova L, Nawrocki M, Kirschner M, Zhao H, Prchal JT, Piwocka K, Moliterno AR, Wasik M, Koschmieder S, Green TR, Skoda RC, Skorski T. Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms. Blood. 2017 Dec 28;130(26):2848-59.   PMCID: PMC5746670
Prudnikova TY, Chernoff J. The Group I Pak inhibitor Frax-1036 sensitizes 11q13-amplified ovarian cancer cells to the cytotoxic effects of Rottlerin. Small GTPases. 2017 Oct 02;8(4):193-8.   PMCID: PMC5680705
Czyz M, Toma M, Gajos-Michniewicz A, Majchrzak K, Hoser G, Szemraj J, Nieborowska-Skorska M, Cheng P, Gritsyuk D, Levesque M, Dummer R, Sliwinski T, Skorski T. PARP1 inhibitor olaparib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomas. Oncotarget. 2016 Nov 15;7(46):75551-60.   PMCID: PMC5342760
Neelakantan H, Tallarida RJ, Reichenbach ZW, Tuma RF, Ward SJ, Walker EA. Distinct interactions of cannabidiol and morphine in three nociceptive behavioral models in mice. Behavioural pharmacology. 2015 Apr;26(3):304-14.
Sasano T, Mabuchi S, Kuroda H, Kawano M, Matsumoto Y, Takahashi R, Hisamatsu T, Sawada K, Hashimoto K, Isobe A, Testa JR, Kimura T. Preclinical efficacy for AKT targeting in clear cell carcinoma of the ovary. Molecular Cancer Research. 2015 Apr;13(4):795-806.   PMCID: PMC4398602
Badawi AF, Eldeen MB, Liu Y, Ross EA, Badr MZ. Inhibition of rat mammary gland carcinogenesis by simultaneous targeting of cyclooxygenase-2 and peroxisome proliferator-activated receptor gamma. Cancer Research. 2004 Feb;64(3):1181-9.
Takahashi N, Li W, Banerjee D, Guan Y, Wada-Takahashi Y, Brennan MF, Chou TC, Scotto KW, Bertino JR. Sequence-dependent synergistic cytotoxicity of ET-743 and paclitaxel in human breast cancer cell lines in vitro and in vivo. Cancer Res. 2002 Dec;62(23):6909-15.
Langer CJ. The emerging world role of irinotecan in lung cancer. Oncology (Huntingt). 2001 Jul;15(7 Suppl 8):15-21.
Takahashi N, Li WW, Banerjee D, Scotto KW, Bertino JR. Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells. Clin Cancer Res. 2001 Oct;7(10):3251-7.
Yang WL, Frucht H. Activation of the PPAR pathway induces apoptosis and COX-2 inhibition in HT-29 human colon cancer cells. Carcinogenesis. 2001 Sep;22(9):1379-83.
Langer CJ. The role of tegafur/uracil in pulmonary malignancy. Drugs. 1999 Jan;58 Suppl 3:71-5.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Drug Synergism

Drug Synergism drug effects pharmacology drug therapy Antineoplastic Agents metabolism administration & dosage Human Mice genetics Cisplatin Apoptosis Female Xenograft Model Antitumor Assays Cultured Tumor Cells Antineoplastic Combined Chemotherapy Protocols Paclitaxel Cell Division Tumor Cell Line US Gov't Support-PHS pathology Phthalazines Non-US Gov't Support Transcription Factors biosynthesis Animal Disease Models Ovarian Neoplasms Doxorubicin Poly(ADP-ribose) Polymerase Inhibitors Signal Transduction Prostaglandin-Endoperoxide Synthase Isoenzymes Camptothecin Cyclooxygenase Inhibitors Dioxoles DNA Repair Clinical Trials Lung Neoplasms Inhibitory Concentration 50 Cytoplasmic and Nuclear Receptors Non-Small-Cell Lung Carcinoma therapeutic use Isoquinolines Piperazines analogs & derivatives antagonists & inhibitors Myeloproliferative Disorders Double-Stranded DNA Breaks cdc Genes Multiprotein Complexes Calreticulin Heterografts ad [Administration & Dosage] Phosphorylcholine Down-Regulation Pyrimidines p21 inactivated kinase Fluorouracil Neoplasm Drug Resistance Phytogenic Antineoplastic Agents Drug Combinations Proto-Oncogene Proteins c-akt DNA Ligase ATP EC 1-14-99-1 (Prostaglandin-Endoperoxide Synthase) Thiazoles United States pd [Pharmacology] Protein Kinase Inhibitors 61-90-5 (Leucine) de [Drug Effects] Tegafur pc [Prevention & Control] Pyrazines Uracil radiotherapy Flow Cytometry Acetophenones Cell Cycle Clear Cell Adenocarcinoma Melanocytes ovarian cancer DNA Fragmentation Anticarcinogenic Agents Acute Pain Pyrazoles Morphine Human Chromosomes-Pair 11 Cytoplasmic and Nuclear) 0 (Receptors 0 (Carcinogens) enzymology Melanoma ag [Agonists] physiology Fluorenes protein kinase oncogene 169590-42-5 (celecoxib) HT29 Cells Thrombopoietin Receptors Acetic Acid 0 (Cyclooxygenase Inhibitors) Survival Analysis 684-93-5 (Methylnitrosourea) Rats Tretinoin aa [Analogs & Derivatives] Breast Neoplasms Cell Line Cannabidiol P-Glycoprotein Carcinogens use chromosomal amplification 35661-60-0 (N-(fluorenyl-9-methoxycarbonyl)leucine) Experimental Mammary Neoplasms 0 (Fluorenes) Dacarbazine ai [Antagonists & Inhibitors] Piperidines Dinoprostone deficiency 0 (15-deoxyprostaglandin J2) Sarcoma Fluorescence Microscopy Nude Mice Synthetic Lethal Mutations pharmacokinetics melanoma Benzopyrans EC 1-14-99-1 (cyclooxygenase 2) Leucine ph [Physiology] Adjuvant Radiotherapy Janus Kinase 2 0 (Sulfonamides) 41598-07-6 (Prostaglandin D2) sensitized screen Methylnitrosourea bi [Biosynthesis] en [Enzymology] Trimetrexate 0 (Anticarcinogenic Agents) Drug Administration Schedule Histones Opioid Analgesics Sprague-Dawley Rats Enzyme-Linked Immunosorbent Assay signal transduction synthetic lethality Treatment Outcome
Last updated on Wednesday, August 12, 2020